A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Uterine Serous Carcinoma
DRUG: ZN-c3
Frequency and severity of TEAEs and incidence of dose modifications, To determine the safety and tolerability of ZN-c3 in subjects with recurrent or persistent USC., 2 years|Objective Response Rate as defined by the revised RECIST v1.1 as assessed by ICR, To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC, 2 years
Objective Response Rate as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator., To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules, 2 years|Duration of Response as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator., To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules, 2 years|Progression Free Survival as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator., To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules, 2 years|Clinical Benefit Rate as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator., To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules, 2 years|Time To Response as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator., To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules, 2 years
This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or persistent uterine serous carcinoma (USC).